The Global. It was a known news in the sector that is about to become a reality much sooner than expected. The biopharmaceutical company Boehringer Ingelheim has reported that after phase III clinical trials on its molecule BI 695501 (adalimumab), whose original biologic is AbbVie's Humira, it is on the verge of starting the procedures for regulatory approval in key markets such as the United States United and Europe. Specifically, the company is about to take this step after verifying the equivalence in efficacy and similar safety profile between BI 695501 and Humira (adalimumab) in patients with active rheumatoid arthritis (RA). With which this biosimilar drug would become the first of its kind belonging to the company and would act as a battering ram in the development of future compounds similar to original biologicals.

READ MORE